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We have developed an animal model of degeneration of the nigrostriatal dopaminergic neurons, the neuronal system involved
in Parkinson’s disease (PD). The implication of neuroinflammation on this disease was originally established in 1988, when the
presence of activated microglia in the substantia nigra (SN) of parkinsonians was reported by McGeer et al. Neuroinflammation
could be involved in the progression of the disease or even has more direct implications. We injected 2 μg of the potent
proinflammatory compound lipopolysaccharide (LPS) in diﬀerent areas of the CNS, finding that SN displayed the highest
inflammatory response and that dopaminergic (body) neurons showed a special and specific sensitivity to this process with the
induction of selective dopaminergic degeneration. Neurodegeneration is induced by inflammation since it is prevented by anti-
inflammatory compounds. The special sensitivity of dopaminergic neurons seems to be related to the endogenous dopaminergic
content, since it is overcome by dopamine depletion. Compounds that activate microglia or induce inflammation have similar
eﬀects to LPS. This model suggest that inflammation is an important component of the degeneration of the nigrostriatal
dopaminergic system, probably also in PD. Anti-inflammatory treatments could be useful to prevent or slow down the rate of
dopaminergic degeneration in this disease.
1. Introduction
The pathological hallmark of Parkinson’s disease (PD), an
age-related neurodegenerative disorder, is the specific and
progressive degeneration of dopaminergic neurons in the
substantia nigra pars compacta (SNpc) [1]. This results
in extrapiramidal motor dysfunction accompanied by pro-
gressive impairment of autonomy, mood, and cognitive
functions [1–3]. Although some genes have been identified
as responsible for rare familial early onset PD [4], its
etiology remains elusive and many distinct possibilities have
been pointed out for that. The eﬀects of exogenous agents,
infection, inflammatory response, and selective oxidative
stress in the SN have been suggested as the most probable
causes of the dopaminergic degeneration in the SN [5]. Many
exogenous compounds have been described to produce
degeneration of dopaminergic neurons in the nigrostri-
atal system, as 6-hydroxydopamine (6-OHDA), 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone and
many other pesticides [6], which suggest an energetic
metabolism impairment as main cause of the disease. Other
possibilities were also proposed, as head trauma, encephali-
tis, reduced expression of trophic factors, alterations of
the ubiquitin-proteasome system and neuroinflammatory
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mechanisms that are thought to collaborate in the progres-
sive demise of SNpc neurons [1, 3, 7–13].
The implication of neuroinflammation as a component
of the neurodegeneration progress of the disease was orig-
inally established in 1988 when the presence of activated
microglia in the SN of PD was reported (see [14]; for review
see [15, 16]). In that moment, the fact that many cases of
PD were accompanied with a general brain inflammation
along with the neurodegeneration was pointed out [14,
17, 18]. The dramatic proliferation of reactive amoeboid
macrophages and microglia seen in the SN of parkinsonian
brains, together with oxidative stress, was highly compatible
with the existence of an inflammatory process similar to that
previously described for Alzheimer’s disease (AD) [19] and
multiple sclerosis [20].
All these data allowed suggesting the implication of
inflammation in the neurodegeneration of nigrostriatal
dopaminergic neurons; however, its importance was not
clear. Is this process exclusively involved in the progress of
degeneration or could it have other implications? Is it able to
induce the neurodegeneration of dopaminergic neurons?
To address these questions, we took advantage of li-
popolysaccaride (LPS), a component of the Gram-negative
bacteria cell wall. LPS is a potent inducer of inflammation
and has diverse eﬀects on cells of the immune system [21].
It was described that the intracerebral injection of LPS
activated glial cells in vivo [22–26]; these microglial cells
could contribute to the neurotoxicity by secreting neurotox-
ins [27–32] including inflammatory cytokines, N-methyl-D-
aspartate (NMDA) receptor agonists, oxygen free radicals,
and nitric oxide (NO). Besides, in vitro studies [33] showed
that dopaminergic neurons were twice as sensitive to the
toxic eﬀects of LPS as tyrosine hydroxylase (TH) negative
neurons. All these data suggested that the injection of LPS
in diﬀerent areas of the brain could be a good experimental
model to ascertain the importance of inflammation in such
diﬀerent areas and neurons.
2. Nigral Dopaminergic Neurons
Degeneration (Loss) Produced by
the Inflammatory Processes Induced by
the Intranigral Injection of LPS
We injected 2 μL of a solution containing 1 mg of LPS/mL
and 1% Monastral blue inert tracer in phosphate-buﬀered
saline [34] in the left SN of female rats previously anes-
thetized. The results showed a significant inflammation with
activation of microglia, a typical characteristic of brain
inflammation. This eﬀect was accompanied by the loss of
dopaminergic neurons (Figure 1) and the decrease of the
intracellular content of dopamine (DA) and its metabolites
in SN and striatum. These eﬀects suggested the loss of
dopaminergic neurons of SN along with its terminals in
striatum. This was corroborated by the loss of TH activity,
mainly in striatum. The highest loss was found 15 days
after the lesion and maintained during the 21 days of the
experiments. The average loss of the dopaminergic system
was around 35%; at this level, rats showed no obvious
motor disturbances. Another interesting result came from
serotonin (5-HT); although 5-HT levels in the SN reached
a minimum 15 days after the lesion, they recovered to the
initial levels by day 21. These results obviously suggested that
the degenerative process induced by inflammation (LPS) in
the SN was specific for dopaminergic neurons and allowed
us to suggest that the injection of a single dose of LPS
within the SN could be an interesting model for studying the
selective eﬀects of inflammatory reactions on dopaminergic
system, and potentially for studying PD. Moreover, taking
into account that Andersson et al. [23] had shown a loss of
pyramidal cells in the CA1 field in mice following an acute
intrahippocampal infusion of 2 μg of LPS, we used this dose
to study the specificity of the LPS eﬀect in diﬀerent areas and
neurons of the brain. Specificity would obviously increase the
importance of the eﬀect.
3. The SN Is the Most Sensitive Area of the
Brain to the Inflammation Induced by the
Injection of LPS, Which Produced a Selective
Degeneration of Dopaminergic Neurons
We injected 2 μL of the LPS solution described before into
four diﬀerent locations: the left SN, the medial forebrain
bundle (MFB), the striatum, and the dorsal raphe nucleus
(DR) [35]. LPS induced a strong macrophage/microglial
reaction in SN, with a characteristic clustering of ma-
crophage cells around blood vessels. These macrophage
cells contained blue particles inside (from Monastral blue),
indicating phagocytic activity. Fifteen days after injection,
the number of lipid-laden cells began to decrease gradually
and 1 year after injection most of the OX-42-positive
cells showed ramified morphology. The SN was far more
sensitive than the striatum and the other areas studied to the
inflammatory stimulus. Moreover, only the dopaminergic
neurons of the SN were aﬀected, with no detectable damage
to either the GABAergic or the serotoninergic neurons. The
damage to the DA neurons in the SN was permanent, as
observed 1 year after injection. Moreover, the injection of
LPS into MFB did not produce any significant eﬀect on the
inflammation process, nor neuronal degeneration. Similar
results were found when injections were made within the
striatum or the DR. Therefore, these results seem to support
that the injection of a single dose of LPS within the SN
produced a selective eﬀect on the dopaminergic neurons.
Moreover, this work pointed out that inflammation was
able to induce the degeneration of nigral dopaminergic
neurons; the induction of inflammatory processes could be
involved in the degeneration of dopaminergic neurons after
injury (as boxing) or infection; it could also be involved in
the progression of neuronal degeneration induced by other
causes. Kim et al. [36] published the same conclusions. They
also studied the eﬀect of LPS injection within hippocampus
and found no significant induction of inflammation or
neuronal degeneration. Neurotoxicity after intraparenchy-
mal injection of LPS has also been reported by other authors
[37, 38].
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Figure 1: Eﬀect of LPS on glial cells and dopaminergic neurons. (a) Injection of vehicle within the SN; (b) injection of LPS. OX-6 is a
commercial antibody directed against a monomorphic determinant of the rat major histocompatibility complex (MHC) class II antigens,
expressed by activated microglia but not for the resting cells. LPS increases OX-6 immunoreactivity around the injection track, filling the area
of activated microglia characterized by its round morphology. On the contrary, there is an area lacking GFAP immunoreactivity, a marker
of astroglia, around the injection site of LPS. As hallmark of this model, LPS induces the loss of dopaminergic (TH positive) neurons in the
SN. Scale bar: 500 μm. (c) Represents the average values of some parameters in the SN (as percentage of controls) after the single injection of
2 μg of LPS: DA/TH/DAT, dopamine content, neurons expressing tyrosine hydroxylase, and dopamine transporter; OX-42/OX-6, density of
activated microglial cells; amounts of the proinflammatory cytokines TNF-α and IL-1β, the adhesion molecule ICAM-1, the inducible nitric
oxide synthase (iNOS), and the heat shock protein (HSP)-70; the phosphorylated (active) forms of the MAP kinases p38 (associated with
promotion of apoptosis) and Akt (cell surviving signal). Alterations on the expression of GFAP and the endothelial barrier antigen (EBA),
as area lacking expression (in mm2), are also shown.
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4. Protective Effect Produced by the Treatment
with Anti-Inflammatory Compounds on This
NeurodegenerativeModel
Obviously, the possible protective eﬀect of an anti-inflam-
matory compound would support this model along with
the importance of the inflammatory response in the LPS-
induced degeneration of the nigral dopaminergic neurons.
Inflammation is an attractive pharmacological target since
it progresses over several days after injury and because
intervention with anti-inflammatory agents may not result
in intolerable side-eﬀects [39].
4.1. Dexamethasone. Thus, we used dexamethasone, a potent
anti-inflammatory drug. It was known that glucocorticoids
were potent anti-inflammatory drugs that have long been
used in clinical neurology for the treatment of brain inflam-
mation [40, 41] and spinal cord injury [42]. They are potent
inhibitors of the IFN-induced activation of microglia and
macrophages in vitro [43] and downregulates the expression
of the major histocompatibility complex (MHC) class II
molecules on macrophages, both in vivo and in vitro [44].
Dexamethasone prevents the induction of cyclo-oxygenase
(COX)-2 mRNA and prostaglandins in the lumbar spinal
cord following intraplantar injection of Freund’s complete
adjuvant, in parallel with inhibition of edema [45]. More-
over, dexamethasone down-regulates the expression of MHC
class II on rat microglia [43, 46] and reversibly inhibits the
microglial proliferation in vitro [47] induced by axotomy and
IFN-γ.
When animals were treated with dexamethasone [48], we
found a significant protection against the damage caused by
the intranigral injection of LPS. The treatment with dexam-
ethasone interferes with many of the features characterizing
proinflammatory glial activation, proliferation and also the
upregulated expression of the MHC class II produced by
LPS. We found that dexamethasone inhibited not only the
number of OX-42-positive cells but also the number of
microglia/macrophages expressing MHC class II antigens as
revealed by staining with OX-6. These observations were in
agreement with previous works reporting that glucocorti-
coids downregulate MHC class II [43, 44, 46].
Dexamethasone treatment was also able to prevent the
loss of DA and its metabolites in SN and striatum. Similarly,
it also prevented the loss of TH (measured by its activity and
by TH immunostaining) in SN and striatum. These results
confirmed that inflammatory response was implicated in
LPS-induced neurodegeneration and open the possibility to
use anti-inflammatory drugs to slow down the progress of
the disease.
4.2. Minocycline. We have used other anti-inflammatory
compounds; minocycline is a semisynthetic tetracycline
derivative that is able to cross the BBB, reaching the cere-
brospinal fluid [49]. Moreover, this new antibiotic exerts
anti-inflammatory eﬀects that are completely separated and
distinct from its antimicrobial origin [50–52]; its use in
neurodegenerative diseases has been suggested. Minocycline
has been shown to protect hippocampal neurons against
global ischemia [53] and to reduce cortical infarction volume
in a rat model of focal brain ischemia [54]. It is also a
very eﬃcient neuroprotective agent in animal models of
traumatic brain injury [55], multiple sclerosis [56], Hunt-
ington’s disease [57], and amyotrophic lateral sclerosis [58].
Moreover, other studies had also demonstrated a neuropro-
tective eﬀect of minocycline over the dopaminergic system in
response to either MPTP [59, 60] or 6-OHDA [61].
When we evaluated the potential neuroprotective activity
of minocycline in our animal model of Parkinson’s disease
induced by the intranigral injection of LPS [62], we found it
was very eﬀective preventing diﬀerent inflammatory features
along with the loss of nigral dopaminergic neurons. Minocy-
cline treatment highly prevented the activation of reactive
microglia as visualized by OX-42 and OX-6 immunohisto-
chemistry, as well as the induction of interleukin (IL)-1α
and tumor necrosis factor (TNF)-α mRNAs. Moreover,
minocycline treatment also partially prevented the loss of
dopaminergic neurons (12% against 50%) produced by LPS.
4.3. Simvastatin. At this time, some experimental and clini-
cal evidence indicated that statins—extensively used in med-
ical practice as eﬀective lipid-lowering agents through the
inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase—
had other cholesterol independent eﬀects, as improving
endothelial function, decreasing oxidative stress, inhibit-
ing the thrombogenic response in the vascular wall,
immunomodulatory and, anti-inflammatory properties [63–
67]. Thus, we investigated the influence of simvastatin on
the degenerative process of the dopaminergic neurons in our
animal model of Parkinson’s disease [68, 69]. In these works,
we found that simvastatin treatment prevented the inflam-
matory process induced by LPS. Simvastatin prevented
the bulk microglial activation found after LPS injection,
reducing the number of microglia/macrophages expressing
MHC class II antigens (40% of LPS group) as revealed by
immunostaining with OX-6; it also inhibited the activation
of IL-1β, TNF-α, and inducible nitric oxide synthase (iNOS)
produced by LPS. These eﬀects could be, at least, one of
the causes of the prevention of dopaminergic neuronal loss
induced by LPS produced by the simvastatin treatment.
However, simvastatin showed another important eﬀect that
could help to the survival of dopaminergic neurons: sim-
vastatin produced the activation of the neurotrophic factor
BDNF, along with the prevention of the oxidative damage
to proteins, conditions in which BDNF has an important
protective eﬀect. Moreover, it also prevents the main changes
produced by LPS on diﬀerent mitogen-activated protein
kinases, featured as increases of P-c-Jun N-terminal protein
kinase, P-extracellular signal-regulated kinase, p-38, and P-
glycogen synthase kinase and the decrease of the promotion
of cell survival signals such as cAMP response element-
binding protein and Akt. Our results suggest that statins
could delay the progression of dopaminergic degeneration in
disorders involving inflammatory processes.
Many other anti-inflammatory compounds have been
described to act as neuroprotectors in this and other
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models of Parkinson’s disease. Nalaxone, an opiate receptor
antagonist, and its inactive isomer (+)-nalaxone, inhibited
both the activation of microglia and the loss of dopaminergic
neurons induced by LPS in the SN [37, 38]. This eﬀect was
improved when nalaxone was combined with indomethacin
[70]. Triptolide, another anti-inflammatory compound, also
prevents the dopaminergic degeneration induced by LPS
intranigral injection [71]. A similar eﬀect was also produced
by silymarin [72] and catalpol [73], other anti-inflammatory
compounds.
5. Why Does the SN Have a Special
Sensitivity to the Inflammation Induced by
the Injection of LPS?
As described above, our results showed that the inflam-
matory reaction was stronger in SN than in striatum and
other areas studied [34–36]. This was also clear in the
characteristic disappearance of the GFAP immunoreactivity
at the LPS injection site. We suggested at that moment that
the diﬀerences could be due to specific structural diﬀerences
between the SN and other areas. Regarding this, it was
thought that SN had the highest concentration of microglia
in the brain [74] and consequently a high concentration
of the inflammation-related factors produced by these cells,
such as TNF-α and NO. This proposal is supported by
the fact that many anti-inflammatory compounds pro-
tect dopaminergic neurons. However, other authors have
reported more recently that in intact brain, the densities of
CD11b+ microglı´a are similar in SNpc and cortex, although
LPS injection enhanced the number of CD11b+ cells in the
former but not in the latter [75].
Other possibilities have been pointed out, as the increase
in vascularization induced by inflammation in the SN, also
described in a MPTP model of PD that is accompanied by
the increase in the vascular endothelial growth factor (VEGF)
[76]. One of the eﬀects of the change could be the increase
in the BBB permeability that could have some influence in
the sensitivity, since the intranigral injection of VEGF also
induce the degeneration of the dopaminergic system [77].
Another important consequence could be the infiltration
of peripheral monocytes/macrophages, which could act as
protector or neurotoxic [78]. These circumstances could
increase the sensitivity of SN to inflammation.
6. Why Are the Dopaminergic
Neurons of the SN Especially Affected in
Our Inflammation Model?
We had described that dopaminergic neurons were especially
sensitive to inflammation, and this did not occur when LPS
was delivered within the MFB (dopaminergic axons) or the
striatum (dopaminergic terminals). The main suggestion
was that SN was highly vulnerable to oxidative damage [79–
82], taking into account its reduced antioxidative capability
along with its high content on iron and DA [83]. However,
this rationale did not account for the special sensitivity of the
DA neurons with respect to other non-DA neurons within
the SN, such as the GABAergic ones. Although unexplained,
this is very interesting for Parkinson’s disease, in which the
dopaminergic neurons are especially sensitive, probably not
only due to the inflammatory process.
To answer this question, we studied the possible influence
of DA. There was a general agreement on the toxic capa-
bility of DA, which generates redox metabolites including
semiquinone, quinone, zwitterionic 5,6-hydroxyindoles, and
possibly oxygen free radicals. Theoretically, this neurotoxic-
ity also accelerates autooxidation of the released DA, which
results in the generation of free radicals in vivo (Figure 2).
Enhanced DA autoxidation and oxygen free radicals may
initiate a cascade of oxidant stress, leading to injury and
loss of SNc neurons in Parkinson’s disease. This possibility
is supported by increased basal malonaldehyde formation
(lipid peroxidation) and iron content in surviving pigmented
SN neurons [80, 84, 85].
To test the involvement of DA in the degeneration
induced by LPS, we treated albino Wistar rats with dif-
ferent concentrations of α-methyl-p-tyrosine (α-MPT), an
inhibitor of TH activity that blocks synthesis of cytoplasmic
DA [86, 87]. Pretreatment with α-MPT reduces DA content
by 79% [88]. Results showed that α-MPT prevented, in a
dose-dependent manner, the inflammatory features induced
by LPS: activation of microglial cells (characterized by a
change of morphology from resting, ramified cells with thin
processes, to reactive microglial cells that eventually become
phagocytic), loss of the astroglial population accompanied
by the appearance of GFAP immunoreactive debris from
hypertrophic, degenerating astrocytes, loss of TH immunos-
taining, and expression of mRNA for TH and DA transporter
(DAT). These protective eﬀects resulted from inhibition of
TH and the consequent decrease in DA concentration, since
cotreatment with L-DOPA/benserazide, which bypasses TH
inhibition increasing the extracellular levels of DA in the
SN approximately fourfold with respect to basal levels [89],
avoided the protective eﬀects induced by inhibition of TH
produced by α-MPT and restored the degenerative eﬀects
induced by LPS on dopaminergic neurons as well as the
loss of astrocytes. All these results strongly supported the
implication of DA in the dopaminergic neurodegeneration
induced by LPS in the SN. Moreover, not only did DA
seem to be involved in dopaminergic degeneration of the
SN but it could also be responsible for the special sensitivity
of the SN to the inflammation induced by LPS. The SN
inflammatory response to LPS injection after TH inhibition
was similar to that described for other brain areas, where
LPS had little or no eﬀect on neuron degeneration or the
glial inflammatory process [35, 36]. However, the treatment
with LPS + α-MPT + L-DOPA/benserazide did not produce
activation of microglial cells, although it induced damage to
astroglia. This result is quite intriguing and could be involved
in the inflammation process in SN. These results point out
the important contribution of DA to the vulnerability and
degeneration of dopaminergic neurons of the SN. Further
knowledge about the involvement of DA in this process may
lead to the possibility of new protection strategies against this
important degenerative process.
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Figure 2: Interaction between glia and neurons may lead to neuron damage and death. LPS activates microglia from a resting state to an
activated one, probably through the CD14 and the TLR4 receptors; this signalling pathway, mediated by diﬀerent molecular adaptors, kinases,
and MAP kinases, activates NF-κB with the consequent transcription of specific genes leading to microglial activation. Then, activated
microglial cells release several compounds, as proinflammatory cytokines, radical oxygen species (ROS), and NO that may eventually lead to
neuronal death. Within dopaminergic neurons, the mitochondrial respiratory chain can be aﬀected by several substances, leading to energy
failure, production of ROS, and reduction of the neurons viability. ROS can act as signal for the activation of microglia, indicating that
neurons are not healthy. DA can exert a toxic action through the ROS formed in its oxidative metabolism; it may also forms complexes with
cysteine, inhibiting the respiratory chain and producing more ROS. The reduction/elimination of microglial induction could ameliorate
neuronal damage.
7. Other Natural and Endogenous Compounds
Able to Induce the Inflammatory
Process along with the Degeneration of
Dopaminergic Neurons by
Intranigral Injection
LPS is a compound derived from de bacterial cell wall; thus,
it could be considered an exogenous substance to the nervous
system; other natural and endogenous compounds have been
described to have similar properties on this process.
7.1. Histamine. We have evaluated the eﬀects of a direct infu-
sion of histamine (HA) in SN, striatum, medial septum, and
medial lemniscus. There were many reasons for carrying out
these experiments. Histamine is an important component of
mast cells of the brain and participates in the enhancement of
microvascular permeability, leukocyte rolling, adhesion, and
extravasations of inflammatory cells into the brain and spinal
cord. These events are important in many inflammatory
diseases of the CNS, such as encephalomyelitis and multiple
sclerosis [90]. It is also released after trauma, ischemia,
seizures, and inflammation [91]. Moreover, the brain also
has histaminergic neurons located in the tuberomammillary
nucleus of the posterior hypothalamus nucleus that project
to almost all regions of the brain from the olfactory bulb
to the spinal cord [92]. This neuronal HA acts as neuro-
modulator or neurotransmitter [93, 94], participating also in
many physiological functions [93–95]. It also interacts with
some neurotransmitter as DA [96–101]. This relationship
could be involved in the interaction between central HA
neurons with the extrapyramidal system. It is known that
HA induces catalepsy, which has been suggested as an animal
model of Parkinson’s disease [102]. HA antagonists are used
as antiparkinsonian drugs [103].
HA has been shown to be involved in neuronal degenera-
tion [104] and neurotoxicity [105]. Wernicke’s encephalopa-
thy is a disorder characterized by selective pathologic damage
to the midline thalamus, mammillary bodies, and certain
brainstem nuclei. Thiamine deficiency is a critical factor in
the etiology of this disorder. Langlais et al. [104] using a
rat model of Wernicke’s encephalopathy induced by an acute
bout of pyrithiamine-induced thiamine deficiency (PTD),
pointed out that HA mediated neuronal death in this model.
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In our study [106], the injection of histamine in SN pro-
duced an acute inflammatory response manifested by an acti-
vation of microglia, where OX-42-immunoreactive microglia
exhibited typical features of phagocytic cells. In addition, a
marked induction of MHC class II antigen expression and a
characteristic disappearance of the GFAP immunoreactivity
were produced in the same area. These eﬀects were accom-
panied by a selective damage in dopaminergic neurons, evi-
denced by the loss of tyrosine hydroxylase mRNA-expressing
cells, tyrosine hydroxylase-immunolabeled-positive cell bod-
ies, and a decrease of DA and 3,4-dihydroxyphenylacetic
acid levels. However, HA injection had little eﬀect in other
areas; only high doses produced an evident dopaminergic
terminal degeneration. Moreover, similarly to that described
for LPS, HA produced the specific degeneration of DA
neurons of SN; HA did not aﬀect GABAergic neurons, alter
the pattern of ChAT mRNA-expressing cells, or change the
pattern of 5-HT-immunolabeled cells when it was injected
in SN, septum, or the medial lemniscus, respectively. We
conclude that, similarly to LPS, HA is a selective neurotoxin
for dopaminergic cells.
HA eﬀect must be related to its inflammatory capability
along with the rapid and reversible increase in the BBB
permeability, producing a disturbance of the normal brain
homeostasis. Moreover, a direct neurotoxic eﬀect of HA over
the nigral dopaminergic population should never be dis-
carded, since there are reports on the induction of neuronal
death by HA [104, 105]. In spite of the strict and remarkable
selective neurotoxic action of HA on the dopaminergic
system, HA may be taken into account in relationship to
its involvement in the etiopathology of PD. So, higher
blood HA levels have been found in patients with PD than
in healthy controls [107]. However, central histaminergic
systems are not aﬀected in PD [108]. It has been shown that
mast cells can rapidly penetrate brain blood vessels from
extraneuronal sources [109]. It is interesting to note that
therapies used in PD (L-DOPA + carbidopa) decrease the
blood HA concentration [107], probably due to the decrease
in its formation [110]. In addition, HA antagonists have long
been used as antiparkinsonian drugs [103]. Patients with
idiopathic PD treated with famotidine, an HA H2 antagonist,
demonstrated improvement in their motor symptoms [111].
In addition, some HA metabolites and derivatives have
been correlated with the degree of severity in PD patients.
Levels of pros-methylimidazolacetic acid in cerebrospinal
fluid showed a high positive correlation with the severity
of PD in a group of not medicated, mildly to moderately
aﬀected patients [112, 113]. Further indications supporting
the involvement of HA in the etiopathology of PD come from
the observation that an increase in HA concentration was
associated with the appearance or worsening of parkinsonian
symptoms. Thus, acute tacrine administration produced
tremulous jaw movements that shared some characteristics
with parkinsonian tremor [114–116]. Tacrine is an inhibitor
of brain histamine N-methyltransferase, which increases
brain HA concentration [117]. Combined treatment with
tacrine and haloperidol increases the parkinsonian-like
symptoms [118, 119]. Secondary Parkinsonism has been
described in neurocysticercosis [120, 121], characterized by
a diﬀuse brain edema [122] generally accompanied by an
increase of HA levels.
In conclusion, we showed for the first time that HA
was able to produce a specific degeneration of dopaminergic
neurons in SN along with a highly inflammatory process. The
dose of HA needed to produce this eﬀect was remarkably
lower than that described in other studies. Besides, many
of the relationships between elevated HA concentration and
parkinsonism-like symptoms were pointed out. All these
data strongly suggested an important relationship between
elevated concentrations of HA and degeneration of the
nigrostriatal dopaminergic system, which requires further
investigation.
7.2. Thrombin. Thrombin is a multifunctional serine pro-
tease, best known for its role in the blood coagulation cas-
cade. It is derived from its zymogen, prothrombin, and con-
verts fibrinogen into fibrin. It has many functions: activates
platelets, stimulating the proliferation of vascular smooth
muscle cells [123–125]; it is involved in the chemotaxis and
adhesion in monocytes, macrophages, and neutrophils (for
review, see Grand et al. [126]); it has specific eﬀects in cells
of the CNS, regulating neurite outgrowth in neuronal cells
[127] and inducing the proliferation of astrocytes [128];
it is also able to induce the activation and proliferation
of cultured rodent microglia along with the production
of nitric oxide (NO); it evokes the release of cytokines
and chemokines [129] and induces the proliferation of
astrocytes [128, 130]. The latter eﬀects could be important in
relationship to inflammatory processes. It is also interesting
that brain contains this and some other proteases, along
with protease-activated receptors (PARs) that serve key roles
in blood coagulation and wound healing. These proteases
have actually been found in the brain in situations in
which the BBB is compromised, with a possible role in the
neuropathological triggering of this situation (for review,
see Gingrich and Traynelis [131]). Taking into account all
these properties, along with the possible eﬀect of thrombin
in stroke, we studied thrombin eﬀects on the nigrostriatal
dopaminergic system.
Following the experimental procedure carried out in our
previous works, we injected diﬀerent amounts of throm-
bin into the nigrostriatal pathway [132]. Seven days after
injection, we found a strong inflammatory response in the
SN with a strong macrophage/microglial reaction pointed
out by immunostaining (using OX-42 and OX-6 antibodies)
and the induction of iNOS, IL-1α, Il-1β, and TNF-α. These
results showed that the infusion of thrombin induced an
inflammatory process in a similar way to other proinflam-
matory compounds such as LPS, probably by the activation
of microglial cells, as described for microglial cultures [129].
The thrombin-induced inflammation was produced by its
biological activity, maybe through the protease-activated
receptors- (PAR-) receptor, since the injection of heat
denatured thrombin or thrombin plus α-NAPAP (a specific
inhibitor of thrombin) did not induce these processes, or
they were strongly reduced. Moreover, selective damage
to dopaminergic neurons was produced after thrombin
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injection, evidenced by loss of TH immunostaining and
TH mRNA expressing cell bodies, and the unaltered tran-
scription of glutamic acid decarboxylase (GAD) mRNA in
the SN and striatum. These eﬀects were also produced
by its biological activity since they almost disappeared when
thrombin was heat-inactivated or injected with its inhibitor
α-NAPAP.
These thrombin eﬀects were even more interesting if
we remember that thrombin is activated from prothrombin
in the coagulation cascade and also that it enters inter-
stitial fluid during penetrating head wounds, hemorrhagic
stroke, rupture of cerebral aneurysms, and arteriovenous
malformations. In addition, BBB breakdown associated
with cerebrovascular insults reflects a largely nonselective
increase in the permeability of brain capillaries and tight
junctions to high molecular weight proteins. Moreover,
taking into account that prothrombin circulates in blood at
high concentrations (1 μM) [133] and vascular injury
triggers its rapid conversion to thrombin, direct entry of
thrombin into the interstitial space with the consequence of
a significant increase in its concentration is plausible [134].
Moreover, the elevation of thrombin levels in cerebrospinal
fluid from 100 pM to 25 nM for a period of more than
a week has been reported in subdural hematoma [135].
This suggests that appreciable amounts of thrombin can
be generated and persist at sites of cerebrovascular injury.
When bleeding occurs directly within brain tissue, active
thrombin, and other proteases will freely penetrate the
interneuronal spaces by diﬀusion until clotting closes the
injured vessels and thrombin becomes depleted from the
clot. High concentrations of thrombin, such as those that
can be produced by a cerebral hemorrhage, appear to
cause brain damage [133, 136] and may also contribute to
damage in Alzheimer’s disease and vascular dementia [137–
139]. Vascular Parkinsonism has also been reported [140];
moreover, features of Parkinsonism have been seen in up to
38% of lacunar stroke patients at one year [141].
All these data provided evidence that thrombin activates
microglia along with other inflammatory features in the SN,
resulting in specific degeneration of dopaminergic neurons.
These results suggest that thrombin, as an endogenous
neurotoxin, could be implicated in dopaminergic neuron
degeneration. Besides PD, these features could also be of rele-
vance for a wide range of neurological diseases which present
pathological signs of inflammation, such as cerebrovascular
diseases and CNS trauma.
Similar results were described by Choi et al. [142]. It
is interesting to note that the inflammatory process and
the degenerative induction produced by intranigral injection
of thrombin are not overcome by the treatment with
dexamethasone as anti-inflammatory agent [143]. In fact,
when we studied the possible protection exerted by dexam-
ethasone in the thrombin paradigm, we found unexpected
results. Dexamethasone was able to prevent partially the
loss of astrocytes but was unable to overcome other inflam-
matory features, as the microglial proliferation induced by
thrombin. Moreover, this treatment resulted in a greater
loss of dopaminergic neurons that was accompanied by
the accumulation of α-synuclein in dopaminergic neurons,
probably produced by the diminution of its degradation, an
eﬀect described to be produced by dexamethasone on the
beta-amyloid [144]. Dexamethasone produced other eﬀects,
as the consequent aggravation of the ischemic neuronal
damage in striatum [145] and hippocampal CA1 area [146]
as the extracellular accumulation of glutamate increased and
thereby the overload of cellular calcium [147].
We also found that dexamethasone produced a signifi-
cant decrease in PAR-1, which was increased by thrombin
plus dexamethasone; nexin-1, the most abundant, potent
endogenous thrombin inhibitor in brain [148], was not
also aﬀected by dexamethasone alone but was increased by
thrombin; the eﬀect was greater and in the same direction
when thrombin and dexamethasone were used together.
Dexamethasone produced a greater amount of oxidative
stress (measured as carbonyl groups) than thrombin, in a
similar extension that in animals treated with thrombin plus
dexamethasone. We suggest that this increase of oxidative
stress could be the cause of the great damage produced
by dexamethasone. The cause of the oxidative stress is
the increase of DA metabolism produced by the release
of DA along with its metabolism through MAO enzymes.
It is known that MAO-A is induced by glucocorticoids
in tissues as human skeletal muscle [149] or bovine
adrenal endothelial cells [150]. Dexamethasone increased
the expression of MAO-B in rat astrocytes, which was
inhibited by the glucocorticoids receptor inhibitor RU486
[151]. Moreover, the relationship between MAO-dependent
H2O2 overproduction and degenerative processes had been
suggested in PD [152]. These data suggested that H2O2
produced by MAO played an important role in the induction
of apoptosis under some conditions. In our experimental
design, both MAO A and B increased in animals treated with
dexamethasone. Moreover, when we blocked MAO activity
with tranylcypromine, the death of dopaminergic neurons
caused by the combined treatment with thrombin and
dexamethasone was prevented. This supports that induction
of MAO activity by dexamethasone might play an important
role in the lack of protection against thrombin observed
in the animals treated with this glucocorticoid. This result
is also in agreement with Tazik et al. [153], who recently
described the protective eﬀect of rasagiline, an inhibitor
of MAO B, on dexamethasone-induced brain apoptosis.
Increase of DA metabolism produced by dexamethasone
through the induction of MAOs could be important in
dopaminergic neurons, since DA seems to play an active role
in their degeneration [154].
7.3. Tissue Plasminogen Activator (tPA). tPA is a highly spe-
cific serine proteinase and one of the two principal plas-
minogen activators. It is widely distributed in all brain
regions across the neuroaxis, being more elevated in the
spinal cord and the SN [155, 156]. Diﬀerent functions
have been suggested for tPA in the CNS; for our work,
the most important was the neurotoxicity eﬀect [157–162].
Diﬀerent animal models had demonstrated that the genetic
deficiency of tPA [159, 163] and its inhibition with the
natural tPA inhibitor neuroserpin [164, 165] were associated
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with a decrease in infarct volume and significant neuronal
survival compared with control animals. Moreover, tPA plays
important roles in blood coagulation and fibrinolysis outside
the CNS. By cleaving the precursor molecule plasminogen,
plasminogen activators produce the active enzyme plasmin,
which dissolves fibrin-based clots in focal cerebral ischemia.
Clinical trials have demonstrated that treatment with plas-
minogen activators in selected patients can improve outcome
after acute ischemic stroke [166]. Moreover, tPA is the only
drug approved for the treatment of thromboembolic stroke,
but it might lead to some neurotoxic side eﬀects. Some
of these eﬀects could be related with the fact that tPA,
as thrombin, is able to induce microglia [167], probably
with the consequent activation of an inflammatory process
that could be responsible for some of the neurotoxic eﬀects
reported after its pharmacological use.
We have used the intranigral injection of tPA, which
let us to describe its eﬀects under standardized conditions.
We found that injection in the SN led to the induction of
inflammatory process, microglial activation, loss of astroglia,
and increase in the expression of nNOS, iNOS, and aqua-
porin 4, along with the disruption of the BBB integrity. This
latter result is in agreement with Yepes et al. [168] and Goto
et al. [169] which showed that recombinant tPA promotes
acute direct neurotoxicity with disruption of the BBB and
increased formation of edema. Moreover, we also found
a dose-dependent loss of dopaminergic neurons, pointed
out by TH-immunoreactivity and changes in the expression
of TH and DAT mRNAs. The toxic eﬀect of tPA seemed
to be specific on dopaminergic neurons of the SN since
the GABAergic population of the ventral midbrain was not
aﬀected.
These results could be related to—and could also
justify—the possible neurotoxic eﬀect produced by tPA in
those pathological conditions which result in a significant
increase of its production and release. It is known that
endogenous tPA activity increases significantly by ischemia
[159]; this eﬀect is prevented in animals with genetic
deficiency of tPA [159, 163] and also by the treatment with
the natural tPA-inhibitor neuroserpin [164, 165]. Ischemia
should be produced early in the SN to observe the degenera-
tion of dopaminergic neurons induced for tPA. However, we
must note that we carried out other experiments in which we
injected tPA intravenously at nearly clinical concentration,
along with the injection of saline solution in the SN in order
to disrupt the BBB; we did not find a significant degeneration
of the dopaminergic system, suggesting that the damage
observed in our model should be produced by the increase in
the endogenous concentration of tPA and its extravasations
by isquemia.
7.4. Trisialoganglioside. The intranigral injection of Trisialo-
ganglioside GT1b, one of the major brain gangliosides,
induced a great inflammatory response along with the
degeneration of dopaminergic neurons [170]. This is also
relevant since gangliosides, a component of membranes, are
also involved in some neurodegenerative processes in which
they accumulate. The ability of these compounds to induce
inflammation could be important.
8. Peripheral Inflammation Enhanced the
Inflammation Produced by the Intranigral
Injection of LPS and, Consequently, the
Degeneration of Dopaminergic Neurons
As we have described above, evidence suggesting that
inflammation may play a central role in the cell loss seen in
PD has been accumulating during years (see [14]; for review
see [15, 16]). Moreover, some relationship between central
inflammation and peripheral could be possible. It is known
that the chance of developing AD is increased twice in aged
persons exposed to systemic infections [171]. Furthermore,
Strang [172] described the increased prevalence of peptic
ulcer prodromal to idiopathic Parkinsonism [173]. Thus,
we were interested in using our animal model of PD to
study the implication of peripheral inflammation [174].
To achieve peripheral inflammation, we used a model of
ulcerative colitis (UC) induced by dextran sulphate sodium
(DSS) ingestion [175]. We described an increase in the levels
of inflammatory markers from serum (TNF-α, IL-1β, IL-6,
and the acute phase protein C-reactive protein). Moreover,
it also increased the inflammatory parameters in SN (TNF-
α, IL-1β, IL-6, iNOS, intercellular adhesion molecule-1
(ICAM-1), and microglial and astroglial populations) caused
by the intranigral injection of vehicle in animals with
UC. Consequently, peripheral inflammation induced by
UC increased all the LPS-induced inflammatory markers
examined in the ventral mesencephalon, demonstrating
that SN becomes more sensitive to central inflammatory
stimulus under conditions of peripheral inflammation. The
inflammatory response of SN was associated to increased
vulnerability of its dopaminergic population. These results
suggest that inflammation produced in a peripheral organ
(intestine) could induce loss of dopaminergic neurons in
the SN, enhancing the inflammation and the dopaminergic
degeneration induced in the SN by a previous inflammation
(LPS). Moreover, we also studied the possibility that leuko-
cyte infiltration through an impaired BBB could be involved
in the deleterious eﬀects of systemic inflammation on nigral
dopaminergic population under conditions of brain inflam-
mation. Brochard et al. [176] had shown lymphocyte T infil-
tration into brain parenchyma in MPTP-intoxicated mice
showing induction of ICAM-1 but no BBB disruption. Our
analysis demonstrated that UC induced ICAM-1 levels in the
ventral mesencephalon; flow cytometry analyses showed that
the amount of circulating monocytes was higher in animals
from the LPS and UC groups (around fourfold) than in
the control animals. Infiltration in the UC + LPS group
increased nearly eightfold. Moreover, using the intravenous
injection of clodronate encapsulated in liposomes (ClodLip),
which produced a peripheral macrophage depletion lasting
5 days in blood, liver and spleen of normal rats and
mice [177–179], we found the reversion of the deleterious
eﬀect of peripheral inflammation on microglial activation,
BBB disruption, astrocytes loss, and degeneration of nigral
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dopaminergic neurons induced by LPS. Taken together, our
results demonstrate that peripheral inflammation induced
by UC contributes to dopaminergic degeneration. Activation
of macrophages seems a decisive factor, since destruction
of this peripheral leukocyte type by ClodLip abolishes the
nocive eﬀects on the ventral mesencephalon associated with
UC. This study shows that BBB disruption may increase
brain susceptibility to subsequent exposure to circulating
leukocytes. This study may also shed light into previous
observations; it described the existence of an increased preva-
lence of peptic ulcer prodromal to idiopathic Parkinsonism
[172, 180]. This has prompted some authors to suggest a
prominent role of inflammation in gastrointestinal tract in
the etiology and pathogenesis of idiopathic Parkinsonism,
including a possible role for Helicobacter pylori infections
[173, 181]. This infective process is the most prevalent in the
world, aﬀecting approximately 50% of the population [182],
and it is considered the causative agent of many gastroin-
testinal and extradigestive conditions. Colonization of gastric
mucosa by H. pylori is accompanied by an inflammatory
response associated with gastric mucosal damage through
the activation of polymorphonuclear neutrophil leukocytes
[183], inflammatory infiltration of lymphocytes, plasma cells
and macrophages in the stomach tissue [184–186], and the
production of pro-inflammatory factors such as IL-8, IL-1,
and TNF-α [187–189].
9. Conclusions
On 1998, we proposed an animal model of PD based on the
inflammatory process triggered by the intranigral injection
of LPS. Afterwards, this model was further developed and
corroborated that the SN had the highest response to
inflammation process induced by LPS with respect to other
brain areas studied. In addition, one of the responses to
inflammation was the specific degeneration of dopaminergic
neurons. The implication of inflammation in the degener-
ation of dopaminergic neurons was also supported by the
protection produced by many diﬀerent anti-inflammatory
compounds. The interest of this model is to point out the
fact that inflammation is the inductor of the degeneration of
dopaminergic neurons, probably in cases as injury, boxing,
infection, and others; it could be important in the progres-
sion of the disease at the same time that it could enhance
the damage induced by the main (unknown) cause of the
disease. Moreover, the interest of the scientific community in
inflammation in PD has increased significantly afterwards.
In all cases, the anti-inflammatory pharmacology could be
important in the disease, and this model could be also
very useful to test anti-inflammatory treatments. Moreover,
the model has allowed pointing out that any endogenous
substance able to induced inflammation or activation of
microglia produced similar eﬀects to LPS. Many endogenous
compounds have been used in this way, as histamine,
thrombin, or tPA among others. Some of them could have
a direct eﬀect in this disease, as stroke or infection. With
respect to the special sensitivity of the SN to inflammation,
there are no clear answers, but its knowledge would be of
interest for the treatment of PD. The special sensitivity of
dopaminergic neurons to inflammation is also of special
interest; in this case, however, the increase of free radicals
production through MAO enzymes and the eﬀect of DA seem
clear. Our model make possible to study other processes, as
peripheral inflammation, which could enhance the eﬀects
produced by central inflammation.
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